Digoxin use in patients with heart failure with reduced ejection fraction

Received: June 27, 2019; Accepted: July 18, 2019; Published: July 22, 2019 Heart failure represents an important cause of morbidity and mortality worldwide. Despite recent advances in the treatment of this condition, majority of patients have a bad prognosis, low functional class and poor quality of life. Recent guidelines have approved new drugs for the management of these patients and many others are under investigation. ENTRESTO, a combination of sacubritil/valsartan and ivabradine reduce the risk of cardiovascular mortality in patients with heart failure with reduced ejection fraction and are recommended in patients who maintain symptomatic despite concomitant use of angiotensin-converting enzyme inhibitors, beta-blockers and aldosterone antagonists [1,2].